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The World Health Organisation (WHO) currently
recommends the use of five artemisinin-based combina-
tion therapies (ACTs) for the treatment of uncompli-
cated Plasmodium falciparum malaria. ACT combines
two effective antimalarial drugs and is the cornerstone
of successful malaria control and ultimately, elimination.
Fixed-dose combinations (FDC) of ACTs are preferred,
as they promote adherence to treatment and reduce the
risk of selecting for drug-resistant parasites.
In order to strengthen the ACT portfolio of FDCs,
which at the time was minimal, the Drugs for Neglected
Diseases initiative (DNDi), together with the WHO Spe-
cial Programme for Research and Training in Tropical
Diseases (TDR), launched the FACT (Fixed Dose Artesu-
nate Combination Therapy) project in 2002, with original
funding from INCO/DEV. The FACT core group also
included the Brazilian government-owned pharmaceuti-
cal company, Farmanguinhos/Fiocruz, the University of
Bordeaux, Universiti Sains Malaysia, Mahidol University
and the Shoklo Malaria Research Unit in Thailand, the
Centre National de Recherche et de Formation sur le
Paludisme in Burkina Faso and the University of Oxford,
combining epidemiological and drug development exper-
tise. Additional competencies in clinical studies, clinical
supplies and regulatory matters strengthened the core
team. Through innovative collaborations with this variety
of partners, the FACT project delivered FDCs of Artesu-
nate (AS) plus Amodiaquine (ASAQ), and AS plus
Mefloquine (MQ). Key contributions in scale-up, indus-
trial production and regulatory filing were still needed to
make the products available to patients, and different
strategies were set up for each product. Both strategies
were based on an initial development within the public
and not-for-profit sector, with an extension to the private
sector when a viable product was available, for registra-
tion, production and distribution.
Sanofi took over the last steps of industrial develop-
ment and regulatory filing for ASAQ and the product
was pre-qualified by WHO in 2008. Since then, ASAQ
has been registered in over 30 countries, mostly in sub-
Saharan Africa and over 120 million treatments have
been delivered - making this the second most widely
used ACT. Deployment was accompanied by a risk-man-
agement plan, together with an extensive training and
educational programme developed by Sanofi. ASMQ
FDC production was scaled up by Farmaguinhos/Fiocruz
and registered in Brazil in 2008. A large intervention
study involving over 23,000 patients was performed by
the National Malaria Control Programme in Brazil show-
ing the efficacy of the product in real-life conditions.
Through a South-South technology transfer, ASMQ FDC
production was transferred to the Indian pharmaceutical
company Cipla to ensure availability in India and South
East Asia. ASMQ FDC was registered in India in 2011
and in Malaysia in early 2012 and is under review for
WHO prequalification.
The FACT project demonstrates that alternative drug
development strategies can make safe, affordable and sus-
tainable treatments available to patients. Diverse partner-
ships gathering a wide range of expertise, from national
programmes ensuring the most appropriate therapy is
used in endemic areas to industrial partners for product
implementation and wide distribution, were key to suc-
cess. Both ASAQ and ASMQ FDCs are critical drugs for
malaria control across Africa, Latin America and South
East Asia.
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